hhdac6

CHDI-390576 is a CNS-permeable, selective and potent dibenzoyl isohydroxamic acid class IIa histone deacetylase (HDAC) inhibitor that inhibits class IIa HDAC 4, HDAC 5, HDAC 7, HDAC 9, and can be used in cancer research.

sEH/HDAC6-IN-1 (compound M9) serves as a selective, orally active dual inhibitor targeting both sEH and HDAC6. It demonstrates IC50 values of 2 nM for human sEH, 0.72 nM for murine sEH, and 5 nM for HDAC6. Notably, sEH/HDAC6-IN-1 exhibits analgesic and anti-inflammatory effects [1].

sEH/HDAC6-IN-2 is an effective dual inhibitor of soluble epoxide hydrolase (sEH) and HDAC6, demonstrating IC50 values of 0.9 nM for human sEH, 46.8 nM for mouse sEH, and 8 nM for HDAC6. It is used in research focused on inflammatory pain.

Leuxinostat, an inhibitor of HDAC, exhibits an IC50 of 30 nM against hHDAC6. It suppresses the proliferation of THP1, K562, U937, and MEK1 cells, while also inducing apoptosis in leukemia cells NB4 and MOLT-4. Additionally, Leuxinostat inhibits the expansion of hematopoietic stem cells and demonstrates anti-leukemic activity in a zebrafish model.